Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Open accessThe DOI matches its Crossref record; 80 of the 82 references it cites were found in a registry or an index.
Abstract
Checkpoint blockade immunotherapy targeting the PD-1/PD-L1 inhibitory axis has produced remarkable results in the treatment of several types of cancer. Whereas cytotoxic T cells are known to provide important antitumor effects during checkpoint blockade, certain cancers with low MHC expression are responsive to therapy, suggesting that other immune cell types may also play a role. Here, we employed several mouse models of cancer to investigate the effect of PD-1/PD-L1 blockade on NK cells, a population of cytotoxic innate lymphocytes that also mediate antitumor immunity. We discovered that PD-1 and PD-L1 blockade elicited a strong NK cell response that was indispensable for the full therapeutic effect of immunotherapy. PD-1 was expressed on NK cells within transplantable, spontaneous, and genetically induced mouse tumor models, and PD-L1 expression in cancer cells resulted in reduced NK cell responses and generation of more aggressive tumors in vivo. PD-1 expression was more abundant on NK cells with an activated and more responsive phenotype and did not mark NK cells with an exhausted phenotype. These results demonstrate the importance of the PD-1/PD-L1 axis in inhibiting NK cell responses in vivo and reveal that NK cells, in addition to T cells, mediate the effect of PD-1/PD-L1 blockade immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 (a.k.a. CD279) is expressed on activated T cells as well as other cells including but not limited to B cells, natural killer (NK) cells, and myeloid cells (Hsu et al., 2018; Nam et al., 2019).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hsu et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Cited by
Items 201–300 of 848
VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Schaafsma, E., Croteau, W., ElTanbouly, M. A., Nowak, E. C., Smits, N. C., Deng, J., Sarde, A., Webber, C. A., Rabadi, D., Cheng, C., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0116 · Cited by 53
Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
Veldman, J., Visser, L., van den Berg, A., & Diepstra, A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101931 · Cited by 56
“This suggests that by interaction with PD-L1 the most functional and responsive NK cells are inhibited [60].”
BackgroundExploiting NK Cell Surveillance Pathways for Cancer Therapy
Barrow, A. D., & Colonna, M. (2019) · Cancers · doi:10.3390/cancers11010055 · Cited by 55
“PD1 and PD-L1 blockade was subsequently found to induce a strong NK cell response demonstrating that NK cells as well as T cells mediate the effects of PD1/PD-L1 blockade immunotherapy, which may be critical in scenarios where tumours express low levels of MHC-I and high levels of PD-L1 [60].”
BackgroundInfluentialJanelle, V., & Delisle, J. (2021) · Cancers · doi:10.3390/cancers13040598 · Cited by 55
“Since NK cells can also express the inhibitory receptor PD-1, it has been found that a blockade of the PD-1/PD-L1 axis can improve NK cell-mediated immunity to tumors, and this response is indispensable for the full therapeutic effect of immunotherapy [160].”
BackgroundBiomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy
Pesce, S., Greppi, M., Ferretti, E., Obino, V., Carlomagno, S., Rutigliani, M., Thorén, F. B., Sivori, S., Castagnola, P., Candiani, S., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00119 · Cited by 50
“Accordingly, studies suggest a role for NK cells in immunotherapy targeting the PD-1/PD-L1 axis (Hsu et al., 2018) and this is clinically relevant for patients with tumors characterized by a T cell resistant (HLA-Ineg) phenotype.”
BackgroundNiu, C. S., Li, M., Zhu, S., Chen, Y., Zhou, L., Xu, D., Xu, J., Li, Z., Li, W., & Cui, J. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.47701 · Cited by 50
“Some studies have shown that PD-1+ NK cells are functionally defective [19, 20, 35], whereas results of others suggest that they are activated NK cells [36, 37].”
BackgroundGuo, X., Chen, S., Wang, X., & Liu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1138483 · Cited by 57
“When ICIs were administrated, NK cells were activated and released proinflammatory factors, which further promoted inflammation and damaged normal lung tissue (75).”
BackgroundMoreo, E., Jarit-Cabanillas, A., Robles‐Vera, I., Uranga, S., Guerrero, C., Gómez, A. B., Mata-Martínez, P., Minute, L., Araujo‐Voces, M., Felgueres, M. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41768-8 · Cited by 48
Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy
Ijsselsteijn, M. E., Pamplona, R. S., Hermitte, F., & de Miranda, N. F. C. C. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.05.003 · Cited by 54
Cho, Y., Choi, M. G., Kim, D. H., Choi, Y. J., Kim, S. Y., Sung, K. J., Lee, J. C., Kim, S., Rho, J. K., & Choi, C. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00712-2 · Cited by 48
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 51
“APC antigen-presenting cell ARG1 Arginase 1 B2M b2-microglobulin cHL classical Hodgkin’s lymphoma CTL cytotoxic T lymphocyte CAF cancer-associated fibroblast DC dendritic cell DLBCL diffuse large B cell lymphoma DNMTi DNA methyltransferase inhibitor EZH2 enhancer of zeste homolog 2 FDA Food and Drug Administration Fas…”
BackgroundInfluentialCRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
Elmas, E., Saljoughian, N., Pereira, M. D. S. F., Tullius, B. P., Sorathia, K., Nakkula, R. J., Lee, D. A., & Kararoudi, M. N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.834002 · Cited by 51
van der Leun, A. M., Traets, J. J. H., Vos, J. L., Elbers, J. B. W., Patiwael, S., Qiao, X., Machuca-Ostos, M., Thommen, D. S., Haanen, J. B. A. G., Schumacher, T. N., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0851 · Cited by 52
“To account for differences in sample size between the blood and tumor samples, bootstrapping was applied when calculating TCR overlap.”
MethodHavunen, R., Kalliokoski, R., Siurala, M., Sorsa, S., Santos, J. M., Cervera-Carrascón, V., Anttila, M. O., & Hemminki, A. (2021) · Cells · doi:10.3390/cells10020246 · Cited by 47
“injection and two weeks after the treatment period (day 77) as described before [18].”
MethodTherapeutic strategies for gastric cancer targeting immune cells: Future directions
Zhao, Y. F., Bai, Y., Shen, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992762 · Cited by 57
Liu, N., Chen, L., Yan, M., Tao, Q., Wu, J., Chen, J., Chen, X., Zhang, W., & Peng, C. (2023) · Research · doi:10.34133/research.0127 · Cited by 41
“Evidence shows that ICI treatment reduces tumor volume even in the absence of T cells in mice, implying that other immune cells, such as NK cells, play important roles in ICI treatment [43].”
BackgroundThe Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance
Prete, A. D., Sozio, F., Schioppa, T., Ponzetta, A., Vermi, W., Calza, S., Bugatti, M., Salvi, V., Bernardini, G., Benvenuti, F., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0168 · Cited by 56
“A protective role of NK cells was previously described in colorectal, gastric, renal, prostate, and hepatic human tumors (39, 40, 54) and NK cells are emerging as important targets in checkpoint blockade therapies (41, 55).”
BackgroundImmune Escape After Adoptive T-cell Therapy for Malignant Gliomas
Wildes, T. J., Dyson, K. A., Francis, C. P., Wummer, B. M., Yang, C., Yegorov, O., Shin, D. H., Grippin, A., Dean, B. D., Abraham, R. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1065 · Cited by 54
“Then with increased tumor Pdl1, NK cells were engaged by PD-1 or PD-L1 blockade to generate antitumor efficacy against MHCIlo tumors.”
BackgroundMethodResultInfluentialPimentel, V. O., Marcus, D., van der Wiel, A. M.-M. A., Lieuwes, N. G., Biemans, R., Lieverse, R. I. Y., Neri, D., Theys, J., Yaromina, A., Dubois, L. J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001764 · Cited by 49
Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
Lee, H., da Silva, I. P., Palendira, U., Scolyer, R. A., Long, G. V., & Wilmott, J. S. (2021) · Cancers · doi:10.3390/cancers13061363 · Cited by 49
“NK cells do not express PD-1 as abundantly as T cells, but rather in the range from 1 to 29% [184,209,210], as a proportion of NK cells, with one study showing that 30–40% of NK cells had strong PD-1 upregulation [211], highlighting PD-1 expression heterogeneity on NK cells.”
BackgroundGranzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver
Censo, C. D., Marotel, M., Mattiola, I., Müller, L., Scarno, G., Pietropaolo, G., Peruzzi, G., Laffranchi, M., Mazej, J., Hasim, M. S., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202149209 · Cited by 46
Self-citationChen, L., Jiang, X., Li, Y., Zhang, Q., Li, Q., Zhang, X., Zhang, M., Yu, Q., & Gao, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108962 · Cited by 50
Wang, M., Krueger, J. B., Gilkey, A. K., Stelljes, E. M., Kluesner, M. G., Pomeroy, E. J., Skeate, J. G., Slipek, N. J., Lahr, W. S., Claudio Vázquez, P. N., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009560 · Cited by 45
Self-citationReitsam, N. G., Märkl, B., Dintner, S., Sipos, É., Grochowski, P., Grosser, B., Sommer, F., Eser, S., Nerlinger, P., Jordan, F. A., et al. (2023) · Cancers · doi:10.3390/cancers15030994 · Cited by 46
Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity
Tsuneyoshi, N., Hosoya, T., Takeno, Y., Saitoh, K., Murai, H., Amimoto, N., Tatsumi, R., Watanabe, S., Hasegawa, Y., Kikkawa, E., et al. (2024) · Stem cell research & therapeutics · doi:10.1186/s13287-024-03810-4 · Cited by 40
Natural killer cells as a promising therapeutic target for cancer immunotherapy
Kim, N., Lee, H. H., Lee, H.-J., Choi, W. S., Lee, J., & Kim, H. S. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01143-y · Cited by 47
Choi, B., Lee, J. S., Kim, S. J., Hong, D., Park, J. B., & Lee, K.-Y. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.042 · Cited by 44
Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade
Lee, B. R., Chae, S., Moon, J., Kim, M. J., Lee, H., Ko, H. W., Cho, B. C., Shim, H. S., Hwang, D., Kim, H. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.128633 · Cited by 49
“Moreover, consistent with a very recent report (30), NK cells also produced more effector cytokines in the absence of tumor PD-L1.”
ResultToffoli, E. C., Sheikhi, A., Höppner, Y. D., de Kok, P., Yazdanpanah‐Samani, M., Spanholtz, J., Verheul, H. M. W., van der Vliet, H. J., & de Gruijl, T. D. (2021) · Cancers · doi:10.3390/cancers13040711 · Cited by 47
“, MHC-Ilo) tumors, where the effects of the therapies were NK cell-dependent, and T cell-sensitive tumors (MHC-Ihi), where the depletion of either CD8+ T cells or NK cells led to similar increases in tumor growth suggesting that also in T cell sensitive tumors, NK cells play a role in the efficacy of PD-1-PD-L1 blocka…”
BackgroundTargeting oral tumor microenvironment for effective therapy
Budi, H. S., & Farhood, B. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02943-5 · Cited by 53
“Although the role of PD-L1/ PD-1 blockade on NK cells is controversial, some studies have reported that targeting this axis can be proposed for boosting the activity of NK cells [275, 276].”
BackgroundImmunotherapies for pediatric cancer: current landscape and future perspectives
Hutzen, B., Paudel, S. N., Naeimi Kararoudi, M., Cassady, K. A., Lee, D. A., & Cripe, T. P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09819-z · Cited by 44
Astragaloside III Enhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN-γ
Chen, X., Chen, X., Gao, J., Yang, H. N., Duan, Y., Feng, Y., He, X., Gong, X., Wang, H., Wu, X., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00898 · Cited by 45
Li, J., Hu, H., Lian, H., Yang, S., Liu, M., He, J., Cao, B., Chen, D. S., Hu, Y., Zhi, C., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.88539 · Cited by 46
“The importance of immune checkpoints beyond T cells in a review of NK cells possibly play an important role in the antitumor response of immune checkpoint blocking, suggesting that the PD-1 axis is important for NK cells in the tumor microenvironment [49] .”
BackgroundResultInfluentialThe basic biology of NK cells and its application in tumor immunotherapy
Jiang, P., Jing, S., Sheng, G., & Jia, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1420205 · Cited by 45
“Blocking the PD-1/PD-L1 interaction can alleviate NK cell inhibition, thereby enhancing their anti-tumor immune function (146).”
BackgroundThe Potential for Cancer Immunotherapy in Targeting Surgery-Induced Natural Killer Cell Dysfunction
Market, M., Baxter, K. E., Angka, L., Kennedy, M. A., & Auer, R. C. (2018) · Cancers · doi:10.3390/cancers11010002 · Cited by 44
“PD-1 expression has also been identified on NK cells and PD-1/PD-L1 blockade releases NK cell inhibition resulting in enhanced anti-tumor activity in various mouse models of cancer [174,175].”
BackgroundNatural Killer Cell-Based Immunotherapy for Cancer: Advances and Prospects
Hu, Y., Tian, Z., & Zhang, C. (2018) · Engineering · doi:10.1016/j.eng.2018.11.015 · Cited by 47
“Thus, the impaired antitumor activity of NK cells could be restored by a PD-1 and PD-L1 blockade [127].”
BackgroundMa, Y., Xia, P., Wang, Z., Xu, J., Zhang, L. H., & Jiang, Y. (2021) · Neoplasia · doi:10.1016/j.neo.2021.07.004 · Cited by 45
Self-citationA photoresponsive antibody–siRNA conjugate for activatable immunogene therapy of cancer
Wang, X., Xiao, X., Feng, Y., Li, J., & Zhang, Y. (2022) · Chemical Science · doi:10.1039/d2sc01672a · Cited by 41
Insights into the tumor microenvironment of B cell lymphoma
Ng, W. L., Ansell, S. M., & Mondello, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02579-9 · Cited by 48
CAR-NK cells in combination therapy against cancer: A potential paradigm
Li, J., Hu, H., Lian, K., Zhang, D., Hu, P., He, Z., Zhang, Z., & Wang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27196 · Cited by 43
Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion
Álvarez, M., Simonetta, F., Baker, J. B., Morrison, A. R., Wenokur, A. S., Pierini, A., Berraondo, P., & Negrin, R. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00007 · Cited by 44
“showed an improvement of PD-1/PD-L1 blockade only on tumor-infiltrating NK cells, where higher expression of PD-1 was observed (22).”
BackgroundResultInfluentialMorton, L. T., Wachsmann, T. L. A., Meeuwsen, M. H., Wouters, A. K., Remst, D. F. G., van Loenen, M. M., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003715 · Cited by 45
Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors
Hou, C., Wang, Z., & Lu, X. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.08.001 · Cited by 44
“61 The recruitment and cytotoxicity of NK cells against tumor cells can be increased by PD-1/PDL-1 inhibitors.”
BackgroundLi, Y., Acharya, G., Elahy, M., Xin, H., & Khachigian, L. M. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.026 · Cited by 38
The Discovery of Biomarkers in Cancer Immunotherapy
George, A. P., Kuzel, T. M., Zhang, Y., & Zhang, B. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.015 · Cited by 45
“Natural killer (NK) cells are cytotoxic lymphocytes that mediate immune response through chemokine and cytokine release [75].”
BackgroundEpigenetic Regulation of NK Cell-Mediated Antitumor Immunity
Xia, M., Wang, B., Wang, Z., Zhang, X., & Wang, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672328 · Cited by 47
“, anti-PD-1, anti-TIGIT, and anti-NKG2A monoclonal Abs) can recover NK cell antitumor capacity (46, 48).”
BackgroundZou, J., Xia, H., Zhang, C., Xu, H., Tang, Q., Zhu, G., Li, J., & Bi, F. (2021) · Cancer Science · doi:10.1111/cas.14932 · Cited by 51
Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers
Tata, A., Dodard, G., Fugère, C., Leget, C., Ors, M., Rossi, B., Vivier, É., & Brossay, L. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1933808 · Cited by 43
Uceda-Castro, R., Margarido, A. S., Cornet, L., Vegna, S., Hahn, K., Song, J., Putavet, D. A., van Geldorp, M., Çitirikkaya, C. H., de Keizer, P. L. J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100821 · Cited by 43
Sarsembayeva, A., Kienzl, M., Gruden, E., Ristić, D., Maitz, K. S., Valadez-Cosmes, P., Santiso, A., Hasenoehrl, C., Brčić, L., Lindenmann, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997115 · Cited by 44
“also identified that, in addition to T cells, NK cells can mediate the effect of anti-PD-1/PD-L1 therapy (35).”
BackgroundHan, D., Han, Y., Guo, W., Wei, W., Yang, S., Xiang, J., Che, J., Zhu, L., Hang, J., van den Ende, T., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007847 · Cited by 45
Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
Li, Y., Liu, J., Gao, L., Liu, Y., Meng, F., Li, X., & Qin, F. X.-F. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.006 · Cited by 44
NK Cell-Based Immunotherapy in Renal Cell Carcinoma
Terrén, I., Orrantia, A., Mikelez-Alonso, I., Vitallé, J., Zenarruzabeitia, O., & Borrego, F. (2020) · Cancers · doi:10.3390/cancers12020316 · Cited by 37
“In vitro and in vivo experiments have shown that PD-1 and PD-L1 blockades elicit a strong NK cell response that is required for the full effect of the immunotherapy [80,96,97].”
BackgroundImmune evasion in renal cell carcinoma: biology, clinical translation, future directions
Wang, X., Lopez, R., Luchtel, R. A., Hafizi, S., Gartrell, B. A., & Shenoy, N. K. (2020) · Kidney International · doi:10.1016/j.kint.2020.08.028 · Cited by 43
Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function
Mantesso, S., Geerts, D., Spanholtz, J., & Kučerová, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.607131 · Cited by 44
“Recently, it was found that NK cells express the immune checkpoint inhibitor PD-1 and that their cytotoxic activity is reduced upon PD-1 engagement in PD-L1 expressing tumors (31).”
BackgroundNatural Killer Cells in Cancer and Cancer Immunotherapy
Raskov, H., Orhan, A., Salanti, A., Gaggar, S., & Gögenür, I. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.032 · Cited by 45
Sung, J., & Cheong, J. (2022) · Cells · doi:10.3390/cells11050768 · Cited by 51
“Combinations of immune checkpoint inhibitors such as CTLA-4 and PD-1, which can target T cells, are also implicated in NK cell-mediated cytotoxicity [103].”
BackgroundMyeloid derived suppressor cells and innate immune system interaction in tumor microenvironment
Pramanik, A., & Bhattacharyya, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120755 · Cited by 44
Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors
Quamine, A. E., Olsen, M. R., Cho, M. M., & Capitini, C. M. (2021) · Cancers · doi:10.3390/cancers13112796 · Cited by 39
“CD16 has low-affinity for the Fc region of IgG antibodies, and it is sufficient alone to trigger activated, resting, and non-educated NK cells to carry out ADCC responses [70].”
BackgroundInfluentialEffects of PD-1 Signaling on Immunometabolic Reprogramming
Boussiotis, V. A., & Patsoukis, N. (2022) · Immunometabolism · doi:10.20900/immunometab20220007 · Cited by 41
Natural killer cells in sepsis: Underprivileged innate immune cells
Kumar, V. (2018) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2018.12.003 · Cited by 45
Natural killer cell awakening: unleash cancer-immunity cycle against glioblastoma
Wang, M., Zhou, Z., Wang, X., Zhang, C., & Jiang, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05041-y · Cited by 41
“PD-1 expression was initially discovered on T cells, and on NK cells later [56].”
BackgroundLi, Z., Duan, D., Li, L., Peng, D., Ming, Y., Ni, R., & Liu, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1382256 · Cited by 44
PPP2R1A mutations portend improved survival after cancer immunotherapy
Dai, Y., Knisely, A. T., Yano, M., Dang, M., Hinchcliff, E., Lee, S., Welp, A. M., Chelvanambi, M., Lastrapes, M. J., Liu, H., et al. (2025) · Nature · doi:10.1038/s41586-025-09203-8 · Cited by 38
“Indeed, the vital roles of NK cells in mediating ICB efficacy and predicting ICB responses have been reported in recent preclinical and clinical studies 45–47 .”
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
Kooshkaki, O., Derakhshani, A., Safarpour, H., Najafi, S., Vahedi, P., Brunetti, O., Torabi, M., Lotfinejad, P., Paradiso, A., Racanelli, V., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145034 · Cited by 40
Escape of tumor cells from the NK cell cytotoxic activity
Cantoni, C., Wurzer, H., Thomas, C., & Vitale, M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mr0820-652r · Cited by 42
Poznanski, S. M., Ritchie, T. M., Fan, I. Y., El‐Sayes, A., Portillo, A. L., Ben-Avi, R., Rojas, E. A. P., Chew, M. V., Shargall, Y., & Ashkar, A. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001933 · Cited by 39
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 39
Adjusting the scope of natural killer cells in cancer therapy
Shen, Z., Meng, X., Rautela, J., Chopin, M., & Huntington, N. D. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01297-4 · Cited by 39
“When combined with individual agents, IL-2v plus anti-PD1 is also less ef fi cacious for disease control than is the full potency of IL-2 plus anti-PD1 because of the reduced binding of IL-2v to IL-2R α [75 – 77].”
InfluentialType I Interferon Receptor on NK Cells Negatively Regulates Interferon-γ Production
Lee, A. J., Mian, F., Poznanski, S. M., Stackaruk, M. L., Chan, T., Chew, M. V., & Ashkar, A. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01261 · Cited by 39
“has shown that PDL1 can also suppress NK cell function by ligating with the PD receptors on NK cells (28).”
BackgroundNANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis
Saga, K., Park, J., Nimura, K., Kawamura, N., Ishibashi, A., Nonomura, N., & Kaneda, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1429-z · Cited by 53
Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells
McNerney, K. O., Karageorgos, S. A., Hogarty, M. D., & Bassiri, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00873 · Cited by 37
The two-faces of NK cells in oncolytic virotherapy
Marotel, M., Hasim, M. S., Hagerman, A., & Ardolino, M. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.005 · Cited by 37
Self-citationGalván-Morales, M. Á., Rodríguez, R. B., Cruz, J. R. S., & Teran, L. M. (2020) · Molecules · doi:10.3390/molecules25235686 · Cited by 42
Yan, Y., Zheng, L., Du, Q., Cui, X., Dong, K., Guo, Y., & Geller, D. A. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01337-6 · Cited by 40
The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury
Sun, Y., Tan, J., Miao, Y., & Zhang, Q. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00742-x · Cited by 40
“NK cells induce tumour immunosurveillance by releasing chemokines and cytokines; the PD-1–PD-L1 axis precisely checks this process [58].”
BackgroundChen, H., Duan, X., Deng, X., Huang, Y., Zhou, X., Zhang, S., Zhang, X., Liu, P., Yang, C., Liu, G., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0374 · Cited by 37
Maya, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511937 · Cited by 41
Yao, P., Liu, Y., Huang, G., Hao, L., & Wang, R. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00583-7 · Cited by 38
A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
Decaup, E., Rossi, C., Gravelle, P., Laurent, C., Bordenave, J., Tosolini, M., Tourette, A., Cros‐Perrial, E., Dumontet, C., Poupot, M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01943 · Cited by 39
Functional and metabolic targeting of natural killer cells to solid tumors
Wang, J., & Matosevic, S. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00523-7 · Cited by 36
Thelen, M., Wennhold, K., Lehmann, J. M., Garcia-Marquez, M. A., Klein, S., Kochen, E., Lohneis, P., Lechner, A., Wagener‐Ryczek, S., Plum, P. S., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00196-x · Cited by 38
Ahluwalia, P. K., Ahluwalia, M., Mondal, A. K., Sahajpal, N., Kota, V. K., Rojiani, M. V., & Kolhe, R. B. (2021) · Cancers · doi:10.3390/cancers13164037 · Cited by 40
“Interestingly, higher infiltration of NK cells was found to be associated with response to anti-PD-1 therapy [97].”
BackgroundPathania, A. S., Prathipati, P., Olwenyi, O. A., Chava, S. P., Smith, O. V., Gupta, S. C., Chaturvedi, N. K., Byrareddy, S. N., Coulter, D. W., & Challagundla, K. B. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.03.010 · Cited by 41
“In NB, the levels of infiltrating CD8T and NK cells correlate with therapy response.(28,29) Elevated levels of programmed death-ligand 1 (PD-L1 or CD274) have been found in NB tumors.”
BackgroundOvercoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer
Gemelli, M. T., Noonan, D. M., Carlini, V., Pelosi, G., Barberis, M. C. P., Ricotta, R., & Albini, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.886440 · Cited by 39
“Several mouse models showed that the therapeutic effect was NK-dependent in MHC-deficient tumors, while in MHCexpressing tumors (T-cell sensitive), NK depletion has the same effect as CD8 T-cell depletion (105).”
BackgroundTumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy
Kang, X., Huang, Y., Wang, H., Jadhav, S., Yue, Z., Tiwari, A. K., & Babu, R. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010061 · Cited by 38
“M2 TAMs, impacting CD8+ T cell function [37–39].”
BackgroundCAR-NK cells: harnessing the power of natural killers for advanced cancer therapy
dos Reis, F. D., Saidani, Y., Martín-Rubio, P., Pamplona, R. S., Stojanovic, A., & Correia, M. P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603757 · Cited by 39
Luci, C., Bihl, F., Bourdely, P., Khou, S., Popa, A., Meghraoui, A., Vermeulen, O., Elaldi, R., Poissonnet, G., Sudaka, A., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.03.018 · Cited by 35
“More specifically, PD1/PD-L1 and TIGIT blockade led to sustained tumor-specific T-cell immunity in an NK cell-dependent manner (Hsu et al., 2018; Zhang et al., 2018).”
Backgroundvan Vloten, J. P., Matuszewska, K., Minow, M. A. A., Minott, J. A., Santry, L. A., Pereira, M., Stegelmeier, A. A., McAusland, T. M., Klafuric, E. M., Karimi, K., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004335 · Cited by 40
“This highlights the potential for OrfV to be incorporated into the current treatment paradigm for ovarian cancer.”
Gameiro, S. R., Strauss, J., Gulley, J. L., & Schlom, J. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221089910 · Cited by 36
Pirozyan, M. R., McGuire, H. M., Emran, A. A., Tseng, H.-Y., Tiffen, J. C., Lee, J. H., Carlino, M. S., Menzies, A. M., Long, G. V., Scolyer, R. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00372 · Cited by 34
“NK cells are known to express PD-1 and other checkpoint receptors (45) and their cytotoxic activity in vitro is increased by PD-1 blockade (46).”
BackgroundFranzén, A. S., Boulifa, A., Radecke, C., Stintzing, S., Raftery, M. J., & Pecher, G. (2024) · Cancers · doi:10.3390/cancers16020388 · Cited by 34
“Additionally, PD1 is in general only expressed on highly activated NK cells, and in the case of some NK cell lines such as NK-92 cells, it is not detectable [40,41].”
BackgroundQu, J., Wu, B., Chen, L., Wen, Z., Fang, L., Zheng, J., Shen, Q., Heng, J., Zhou, J., & Zhou, J. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03046-3 · Cited by 36
Extracellular vesicles: biogenesis mechanism and impacts on tumor immune microenvironment
Yeat, N. Y., & Chen, R. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01182-2 · Cited by 35
“Recent study reported that acute myeloid leukemia-derived EVs decorated with PD-L1 suppress NK cell activation and cytotoxicity [196–198].”
Mutually assured destruction: the cold war between viruses and natural killer cells
Ali, A., Gyurova, I. E., & Waggoner, S. N. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.02.005 · Cited by 34
PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
Zhang, K., Kong, X., Li, Y., Wang, Z., Zhang, L., & Xuan, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.854967 · Cited by 37
Self-citationKaur, K., Chen, P.-C., Ko, M.-W., Mei, A., Senjor, E., Malarkannan, S., Kos, J., & Jewett, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1132807 · Cited by 33
“In another study, PD-1 and PD-L1 blockade induced a strong NK cell response that was found to be indispensable for the full therapeutic effect of immunotherapy (54).”
BackgroundMartins, C. P., Rasbach, E., Heppt, M. V., Singh, P. K., Kulcsár, Z., Holzgruber, J., Chakraborty, A., Mucciarone, K., Kleffel, S., Brandenburg, A., et al. (2024) · Science Advances · doi:10.1126/sciadv.adi2012 · Cited by 33
Therapeutic approaches to enhance natural killer cell cytotoxicity
Stenger, T. D., & Miller, J. S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1356666 · Cited by 34
Metadata
- Authors
- Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., Zhang, L., Iannello, A., Mathur, N., Jardine, K. E., Kirn, G. A., Bell, J. C., McBurney, M. W., Raulet, D. H., & Ardolino, M.
- Affiliations
- University of California, Berkeley (US)
- University of Ottawa (CA)
- Corresponding author
- Raulet, David H.
- Ardolino, Michele
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-09-10
- Volume
- 128
- Issue
- 10
- Pages
- 4654-4668
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6159991
- OpenAlex
- W2890056446
- Cited by
- 817
- References
- 82
- Citations by year
- 2026: 57 · 2025: 96 · 2024: 107 · 2023: 101 · 2022: 106 · 2021: 148 · 2020: 124 · 2019: 68 · 2018: 7
- FWCI
- 37.29
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Cancer Institute (R01CA093678)
- National Institute of General Medical Sciences (T32GM007232)
- National Institute of Allergy and Infectious Diseases (R01AI113041)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- natural killer cells, PD-1, PD-L1, immune checkpoint blockade, cancer immunotherapy, NK cell exhaustion, antitumor immunity, NK cell activation, tumor immunosuppression, MHC expression
- MeSH terms
- Animals, Humans, Immunotherapy, Killer Cells, Natural, Neoplasms, Experimental, Mice, Knockout, K562 Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.